The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more effective than a standard flu shot.

Moderna’s experimental flu vaccine won unanimous FDA panel backing ahead of an Aug. 5 decision.

The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more effective than a standard flu shot.

An FDA advisory committee voted unanimously on June 18 to recommend that a messenger RNA-based influenza vaccine at the center of a recent change of heart by the FDA be approved…